{"page_content": "Notes\nNote 10 \u2013 Right-of-use assets and lease liabilities\nAmounts recognized in the statement of financial position\nThe statement of financial position shows the following amounts relating to lease assets:\n     Other\n \n     fixtures and\n \nDKK thousand\n    Buildings\n fittings\nAs a\nt January 1, 2021\n    116\n,824\n 1,178\nAdditions\n    0\n 1,511\nRetir\nements\n    \n0\n \n0\nReversal of depreciations\n    0\n 0\nDepr\neciation expense\n    -10\n,666\n -1,\n066\nAs at December 31, 2021\n    106\n,158\n 1,\n623\nAs at January 1, 2020\n    84\n,148\n 1,\n484\nAdditions\n    43\n,698\n 581\nRetir\nements\n    -6\n,036\n -1\n43\nReversal of depreciations\n    6\n,036\n 0\nDepr\neciation expense\n    -11,\n022\n -7\n44\nAs at December 31, 2020\n    116\n,824\n 1,178Set out below are the carrying amounts of lease liabilities and the movements  during the period.\n    2021\n \n2020\nAs at January 1\n    119\n,848\n 85\n,760\nAdditions\n    1,\n418  44\n,209\nAccretion of interest\n    2,\n449\n 2,386\nPayments\n    -12,260\n -12,507\nAs a\nt December 31\n    111,\n454\n 119\n,848\nCurrent\n    11,\n686\n 11,392\nNon-curr\nent\n    99\n,769\n 108\n,456\nThe following are the amounts recognized in profit and loss:\nDepreciation expense of right-of-use assets\n    -11,\n732\n -11,\n766\nInterest expense on lease liabilities\n    2,\n449\n 2,391\nT\notal amount recognized in profit and loss\n    -9\n,283\n -9\n,375\n    \nCash\nflow\n    -12,260\n -12,507\nT\notal cash outflow for leases\n    -12,260\n -12,507\nPlease r\nefer to note 15 in the consolidated financial statements for additional information regarding right-\nof-use assets and lease liabilities.107\nZealand Pharma  \u221e  Annual Report 2021Par Fin \u2013 Note 11", "metadata": {"source": "NASDAQ_ZEAL_2021.pdf", "page": 106, "parser": "pypdf", "split_method": "page", "run_time": "2024-05-29 08:35:04"}, "type": "Document"}